Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors

Biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) do not always allow to achieve remission and low inflammatory activity in rheumatoid arthritis (RA), necessitating switching of therapy. Objective: to evaluate the clinical characteristics and features of ph...

Full description

Bibliographic Details

Published in:	Современная ревматология
Main Authors:	A. O. Bobkova, A. M. Lila, A. E. Karateev
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-08-01
Subjects:	rheumatoid arthritis biologic disease-modifying antirheumatic drugs janus kinase inhibitors switching therapy
Online Access:	https://mrj.ima-press.net/mrj/article/view/1616